

**Biocept, Inc.**  
**5810 Nancy Ridge Drive**  
**San Diego, CA 92121**

May 19, 2023

**VIA EDGAR**

U.S. Securities and Exchange Commission  
Division of Corporation Finance  
100 F Street, N.E.  
Washington, D.C. 20549  
Attn: Jessica Ansart

**Re: Biocept, Inc.**  
**Registration Statement on Form S-1, as amended (File No. 333-271355)**  
**Request for Acceleration of Effective Date**

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Biocept, Inc. (the “**Company**”) hereby requests that the Securities and Exchange Commission (the “**Commission**”) accelerate the effective date of the above-referenced Registration Statement on Form S-1 (as amended, the “**Registration Statement**”) and declare the Registration Statement effective as of 9:00 a.m., Eastern Time, on May 22, 2023, or as soon thereafter as possible, or at such other time as the Company or its counsel may request by telephone to the staff of the Commission. This request for acceleration is subject, however, to your receiving a telephone call prior to such time from Cooley LLP confirming this request. The Company hereby authorizes each of Charles J. Bair and Asa M. Henin of Cooley LLP, counsel to the Company, to make such a request on its behalf.

Once the Registration Statement has been declared effective, please orally confirm that event with Asa M. Henin of Cooley LLP at (858) 550-6104, or in his absence, Charles J. Bair of Cooley LLP at (858) 550-6142.

Very truly yours,

Biocept, Inc.

/s/ Samuel D. Riccitelli

By: Samuel D. Riccitelli

Title: Interim President and Chief Executive Officer